Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms

International Urology and Nephrology

Volumn 43, Issue 3, 2011, Pages 619-624

  Faydaci, Gokhan ^a   Kuyumcuoglu, Ugur ^a   Eryildirim, Bilal ^a   Aktas, Alper ^a   Tarhan, Fatih ^a   Tuncer, Murat ^a  

^a Urology Clinic   (Turkey)

Author keywords

Asymptomatic inflammatory prostatitis; Doxazocin; Erectile dysfunction; Lower urinary tract symptoms; Questionary

Indexed keywords

DOXAZOSIN MESYLATE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG RELEASE; ERECTILE DYSFUNCTION; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MALE; NATIONAL HEALTH INSTITUTE CHRONIC PROSTATIS SYMPTOM INDEX; PROSTATE HYPERTROPHY; PROSTATITIS; SCORING SYSTEM; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DOXAZOSIN; ERECTILE DYSFUNCTION; HUMANS; MALE; MIDDLE AGED; PROSTATISM; PROSTATITIS; SEVERITY OF ILLNESS INDEX;

EID: 80555129630     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-010-9847-z     Document Type: Article

References (20)

1. McVary KT (2005) Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47:838-845 (Pubitemid 40745354)
2. Costabile RA, Steers WD (2006) How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 3:676-681
3. Carson CC (2006) Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 97:39-43 (Pubitemid 43356995)
4. Shiri R, Häkkinen JT, Hakama M et al (2005) Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174:205-209 (Pubitemid 40825715)
5. Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Sexual function. BJU Int 95:12-18 (Pubitemid 40704404)
6. Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282: 236-237 (Pubitemid 29343164)
7. Barry MJ, Fowler FJ Jr, O'Leary MP et al (1992) The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 148:1549-1557
8. Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319-326 (Pubitemid 30052683)
9. Marszalek M, Wehrberger C, Hochreiter W et al (2007) Symptoms suggestive of chronic pelvic pain syndrome in an urban population: Prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 177:1815-1819 (Pubitemid 46560646)
10. Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47:824-837 (Pubitemid 40745353)
11. McVary K (2006) Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 97:23-28 (Pubitemid 43356992)
12. Braun MH, Sommer F, Haupt G et al (2003) Lower urinary tract symptoms and erectile dysfunction: Co-morbidity or typical ''Aging Male'' symptoms? Results of the ''Cologne Male Survey''. Eur Urol 44:588-594 (Pubitemid 37336515)
13. Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 44:637-649 (Pubitemid 37542920)
14. Rosen RC, Wei JT, Althof SE et al (2009) Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: Results from the BPH registry. Urology 73:562-566
15. Kirby RS, Andersen M, Gratzke P et al (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin- gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87:192-200 (Pubitemid 32142527)
16. De Rose AF, Carmignani G, Corbu C et al (2002) Observational multicentric trial performed with doxazosin: Evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 68:95-98 (Pubitemid 34136863)
17. Fawzy A, Braun K, Lewis GP et al (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: A multicenter study. J Urol 154:105-109
18. Andersen M, Dahlstrand C, Høye K (2000) Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 38:400-409
19. Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: The prospective European doxazosin and combination therapy (PREDICT) trial. Urology 61: 119-126 (Pubitemid 36151726)
20. Robert G, Descazeaud A, Nicolaïew N et al (2009) Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate 69: 1774-1780